T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer

Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01376674

Enrollment

Registered

2011-06-20

Start date

2011-03-31

Completion date

Unknown

Last updated

2013-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

localised, prostate cancer, radiotherapy, immunology

Brief summary

Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner. In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Localised prostate cancer (node negative) * definitive radiotherapy * informed consent

Exclusion criteria

* medication including steroids or immunosuppressants

Design outcomes

Primary

Measure	Time frame
T-cell-immunity in time-course	During and 3-6 months after radiotherapy

Countries

Germany

Outcome results